Gadolinium Toxicity Injuries & Side Effects
The most severe injuries related to GBCAs are Nephrogenic Systemic Fibrosis and Gadolinium Deposition Disease.
Nephrogenic Systemic Fibrosis (NSF) results in a thickening and darkening of the skin, shortening of the muscles and tendons and other symptoms which can prove to be fatal. NSF has been associated with exposure to GBCA in patients with impaired renal function. In these cases, the gadolinium cannot be removed from the body adequately which can cause increased gadolinium retention.
Gadolinium Deposition Disease (GDD) results in the development of persistent symptoms anywhere from a few hours to several weeks after being injected with a GBCA. The symptoms of GDD include bone pain and pain in the extremities, burning tissue type pain and brain fog. Patients suffering from GDD often describe excruciating pain in the arms and legs. GDD is a progressive disease, with the severity of symptoms increasing over time. This can lead to the loss of uses of arms, legs, hands, feet and other joints. There are treatments available if the condition is diagnosed early on but, in most cases it is incurable. Gadolinium Deposition Disease has only been show to occur in patients who have undergone an MRI or MRA with the use of a gadolinium-based contrast agent.
Originally healthcare providers were told that patients suffering from renal and kidney issues were the only ones who could be adversely affected by the use of gadolinium-based contrast agents. There is now evidence that shows this to be wrong. Even patients with normal kidney function can suffer severe injuries from the use of linear gadolinium-based contrast agents. Almost immediately following, and up to a few months after, an MRI/MRA in which a Linear GBCA is used, patients with normal kidney and renal function can experience the symptoms associated with gadolinium toxicity.